An FDA official said the agency would have no immediate comment.
``The drug held up for three years.
Graham told Senate investigators that he believed the FDA was trying to block publication of his findings noting the higher risk.
Graham planned to present the study Aug. 25, but he immediately hit resistance from his supervisors, who said they were too preliminary.
Galson also said that Vioxx safety follow-up was complicated by the fact that it is unethical to give placebos to arthritic patients, because their pain needs treatment.
But U.S. Rep.
The trial whose results pulled Vioxx off the market was designed to check how well 25 mg of Vioxx did in preventing recurrence of polyps in the colon.
